G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis Via STAT3-Dependent Cancer Stem Cell Activation
Overview
Authors
Affiliations
Increasing evidence suggests that inflammatory cytokines play a critical role in tumor initiation and progression. A cancer stem cell (CSC)-like subpopulation in neuroblastoma is known to be marked by expression of the G-CSF receptor (G-CSFR). Here, we report on the mechanistic contributions of the G-CSFR in neuroblastoma CSCs. Specifically, we demonstrate that the receptor ligand G-CSF selectively activates STAT3 within neuroblastoma CSC subpopulations, promoting their expansion in vitro and in vivo. Exogenous G-CSF enhances tumor growth and metastasis in human xenograft and murine neuroblastoma tumor models. In response to G-CSF, STAT3 acts in a feed-forward loop to transcriptionally activate the G-CSFR and sustain neuroblastoma CSCs. Blockade of this G-CSF-STAT3 signaling loop with either anti-G-CSF antibody or STAT3 inhibitor depleted the CSC subpopulation within tumors, driving correlated tumor growth inhibition, decreased metastasis, and increased chemosensitivity. Taken together, our results define G-CSF as a CSC-activating factor in neuroblastoma, suggest a comprehensive reevaluation of the clinical use of G-CSF in these patients to support white blood cell counts, and suggest that direct targeting of the G-CSF-STAT3 signaling represents a novel therapeutic approach for neuroblastoma.
Kobayashi G, Sekino Y, Nakahara H, Kobatake K, Goto K, Hayashi T J Cancer Res Clin Oncol. 2024; 151(1):18.
PMID: 39739128 PMC: 11685250. DOI: 10.1007/s00432-024-06045-1.
Comprehensive summary: the role of PBX1 in development and cancers.
Liu M, Xing Y, Tan J, Chen X, Xue Y, Qu L Front Cell Dev Biol. 2024; 12:1442052.
PMID: 39129784 PMC: 11310070. DOI: 10.3389/fcell.2024.1442052.
Gene Expression of /CD114 Is Associated with Poorer Patient Survival in Glioma.
Bark S, Dalmolin M, Malafaia O, Roesler R, Fernandes M, Isolan G Int J Mol Sci. 2024; 25(5).
PMID: 38474265 PMC: 10931759. DOI: 10.3390/ijms25053020.
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma.
Mora J, Modak S, Kinsey J, Ragsdale C, Lazarus H Int J Cancer. 2023; 154(8):1340-1364.
PMID: 38108214 PMC: 11703753. DOI: 10.1002/ijc.34815.
Prevention of STAT3-related pathway in SK-N-SH cells by natural product astaxanthin.
Sun S, Du F, Zhang L, Hao-Shi , Gu F, Deng Y BMC Complement Med Ther. 2023; 23(1):430.
PMID: 38031104 PMC: 10685499. DOI: 10.1186/s12906-023-04267-3.